Efficacy of two programmed cell death 1 combination regimens in recurrent and/or metastatic head and neck carcinoma: A real-world retrospective study
BACKGROUND The combination of programmed cell death 1 (PD-1) inhibitors with molecularly targeted agents, including anti-epidermal growth factor receptor monoclonal antibody (cetuximab) and multi-targeted tyrosine kinase inhibitor (such as anlotinib), has emerged as promising therapeutic strategies in recurrent and/or...